NANETS2023 Clinical – Nuclear Medicine/Interventional Radiology/Imaging (24 abstracts)
Small bowel ischemia in patients with midgut neuroendocrine tumors after treatment with 177Lutetium-Dotatate
Eleonora Pelle, MD1, Taymeyah Al-Toubah, MPH1, Ghassan El-Haddad, MD2 & Jonathan Strosberg, MD1
1Department of Gastrointestinal Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL; 2Diagnostic Imaging and Interventional Radiology, Moffitt Cancer Center and Research Institute, Tampa, FL
Background: 177Lutetium (Lu)-Dotatate is a safe and well tolerated treatment for metastatic gastroenteropancreatic (GEP) NETs. However, radiation can cause transient inflammation/swelling of tumors which can result in toxicity. Treatment-related small bowel obstruction associated with mesenteric or peritoneal disease has been described. We investigated the potential for intestinal ischemia in 177Lu-Dotatate treated patients.
Methods: Clinical records of patients with midgut NETs treated with 177Lu-Dotatate at our institution between April 2018 and December 2022 were reviewed.
Results: Among the cases reviewed, we identified 2 patients who developed bowel ischemia/perforation shortly after their initial treatment with 177Lu-Dotatate. Both patients had metastatic small bowel NET with prominent mesenteric mass encasing/obstructing the mesenteric vessels and preexisting symptoms of post-prandial abdominal pain.
Conclusion: Acute bowel ischemia may be a rare complication of PRRT in patients with mesenteric arterial or venous obstruction from mesenteric metastasis.
Abstract ID 23700
Article tools
My recent searches
My recently viewed abstracts
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more